Symptomatic Irreversible Pulpitis (SIP)NCT07239505
A Randomized Controlled Trial Evaluating Whether Pre-operative Trinase Reduces Post-operative Pain in Patients With Symptomatic Irreversible Pulpitis Compared to Placebo, Using VAS Scores and Analgesic Intake Over 48 Hours.
A study testing Trinase in people with Symptomatic Irreversible Pulpitis (SIP) and Postoperative Pain After Endodontic Treatment, run by Fayoum University at 1 site in Egypt.
Trial summary
This study aims to determine whether Trinase, an enzyme-based anti-inflammatory medication, can reduce pain after root canal treatment in patients with symptomatic irreversible pulpitis. Read more about this study
- Who is it for?
- Ages 18 to 50 years, men only
- Conditions the study is for
- Symptomatic Irreversible Pulpitis (SIP), Postoperative Pain After Endodontic Treatment, Endodontic Disease
- What is being tested?
- Trinase
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 400 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Aug 2025to 5 Jan 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- Men only
- No healthy volunteers
- Adult
Who may be able to join
- Systemically healthy male patients (ASA I or II)
- Aged 18 to 50 years
- Presenting with symptomatic irreversible pulpitis in a restorable mandibular molar
- Preoperative moderate to severe pain (VAS ≥45 mm)
- Normal periapical tissue (no radiolucency, pocket depth ≤5 mm, mobility ≤ Grade I)
Who cannot join
- Medically compromised patients (ASA III or higher)
- History of allergy or intolerance to Trinase or any of its components (trypsin, bromelain, rutin)
- Vertical root fracture
- External or internal root resorption
- Periodontal pocket depth >5 mm
- Tooth mobility Grade II or III
- Presence of periapical lesion (radiolucency)
- Female patients (to standardize pain perception and hormonal factors)
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Role Of Trinase In Reducing Post-Operative Pain For Patients With Symptomatic Irreversible Pulpitis: A Randomized Controlled Trial
This study aims to determine whether Trinase, an enzyme-based anti-inflammatory medication, can reduce pain after root canal treatment in patients with symptomatic irreversible pulpitis. A total of 400 male patients aged 18 to 50 years who present with moderate to severe tooth pain were randomly assigned to receive either a Trinase tablet or a placebo 30 minutes before treatment. All root canal procedures were performed in a single visit using standard endodontic techniques.
Pain levels were measured on a Visual Analogue Scale (VAS) before treatment and at 6, 12, 24, and 48 hours after treatment. Patients recorded the number of pain-relief tablets they take during the first 48 hours. The goal of the study is to see whether Trinase can lower post-operative pain and reduce the need for analgesic medication compared with placebo. This information may help improve pain management for patients undergoing root canal therapy.
Read the detailed description
Symptomatic irreversible pulpitis is a common endodontic condition characterized by severe inflammatory dental pain. Although root canal treatment (RCT) is effective in removing the inflamed pulp tissue, many patients continue to experience pain during the first 24-48 hours after treatment. Post-operative endodontic pain affects patient comfort, satisfaction, and clinical workflow, making pain control an essential component of evidence-based endodontic care.
Traditional pharmacological methods for managing post-operative dental pain include nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. While these medications are effective, they are also associated with potential gastrointestinal and systemic adverse effects, especially when used repeatedly. As a result, there is growing interest in alternatives that can reduce inflammation and discomfort while minimizing systemic risks. Enzyme-based anti-inflammatory therapies, including combinations of trypsin, bromelain, and rutin, have been shown in medical and dental literature to provide meaningful reductions in pain, edema, and inflammation following surgical procedures. These proteolytic enzymes act by breaking down inflammatory mediators, reducing tissue permeability, and modulating cytokine responses. Trinase, a formulation containing trypsin, bromelain, and rutin, is widely used in postoperative care in other medical fields, yet its role in managing pain following endodontic procedures has not been adequately studied.
This randomized, double-blind, placebo-controlled clinical trial is designed to evaluate whether administering Trinase before root canal treatment can reduce the intensity of post-operative pain in patients diagnosed with symptomatic irreversible pulpitis. A total of 400 systemically healthy male patients, aged 18 to 50 years, were recruited from the Endodontics Department at Fayoum University. The study population is limited to male participants to standardize biological pain variability and hormonal influences on pain perception. Eligible patients presented with restorable mandibular molar teeth and moderate to severe preoperative pain confirmed both clinically and radiographically.
Participants were randomly assigned to one of two equal study arms. The Trinase group received a single oral Trinase tablet 30 minutes before treatment. The placebo group received a visually identical tablet administered under the same conditions. An assistant not involved in treatment prepared and code all medication envelopes, ensuring allocation concealment. Both the operator and the participants were blinded to group assignment.
All treatments were performed in a single visit using standardized endodontic procedures. After local anesthesia, rubber-dam isolation, and access preparation, canal patency were confirmed using stainless steel hand files. Working length determined electronically and confirmed radiographically. Mechanical instrumentation were performed using Protaper Next rotary instruments according to manufacturer instructions. Irrigation will be performed using 2.5% sodium hypochlorite and EDTA gel lubricant. Upon completion of cleaning and shaping, canals will be dried, obturated using a modified single-cone technique with resin-based sealer, and restored temporarily with intermediate restorative material. All procedures are performed by a single experienced operator to eliminate inter-operator variability.
The primary outcome measure is postoperative pain intensity assessed using a 10-cm Visual Analogue Scale (VAS). Patients will record their pain levels at baseline and at 6, 12, 24, and 48 hours after treatment. Pain will be categorized using validated VAS cutoff values. The secondary outcome measure is the total number of analgesic tablets consumed within 48 hours following treatment. Participants will receive a standardized pain diary to document both pain levels and analgesic intake.
Statistical analysis will be conducted using non-parametric tests due to expected non-normal distribution of pain scores. Between-group differences will be analyzed using the Mann-Whitney test, and within-group comparisons across time points will be performed using the Friedman test followed by appropriate post-hoc analysis. The significance level will be set at p ≤ 0.05. Sample size was calculated using PS software to detect clinically relevant differences in postoperative pain with an anticipated dropout rate accounted for by enrolling 400 participants.
The study protocol has been reviewed and approved by the Fayoum University Supreme Committee for Scientific Research Ethics (FU-SCSRE). Written informed consent will be obtained from each participant. The study involves minimal risk, as Trinase is a commercially available medication with a well-established safety profile and the placebo carries no known risks. The duration of active participation for each subject is approximately 48 hours, corresponding to the postoperative observation period. No additional radiographs or invasive procedures beyond standard clinical care will be performed.
This study aims to determine whether Trinase can serve as a simple, safe, and effective adjunct to improve postoperative patient comfort following root canal therapy. The results may help clarify the role of enzyme-based anti-inflammatory medications in endodontic pain management and potentially reduce reliance on traditional analgesics with known adverse effects.
- Conditions
- Symptomatic Irreversible Pulpitis (SIP), Postoperative Pain After Endodontic Treatment, Endodontic Disease, Dental Pain
- Being tested
- Trinase, placebo capsule
- Keywords
- Visual Analogue Scale (VAS), Randomized Controlled Trial, Trinase, Postoperative Pain
- Medical subject headings
- Dental Pulp Diseases, Toothache, Pain, Postoperative
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TrinaseDrug
One tablet of Trinase (proteolytic enzyme combination: trypsin, bromelain, and rutin) administered orally 30 minutes prior to root canal treatment. Used as premedication to reduce postoperative pain and inflammation.
placebo capsuleDrug
One identical-appearing placebo tablet administered orally 30 minutes prior to root canal treatment. Used as control.
| Study group | Role | What they receive |
|---|---|---|
| Trinase group | Experimental | Patients received one tablet of Trinase (trypsin, bromelain, and rutin) orally 30 minutes before single-visit root canal treatment (RCT). RCT was performed under local anesthesia (2% lidocaine with 1:80,000 epinephrine) using a rubber dam and standard endodontic techniques. Postoperative pain was assessed using the Visual Analogue Scale (VAS) at 6, 12, 24, and 48 hours. Ibuprofen 400 mg was allowed as rescue analgesia if needed, and consumption was recorded. Receives: Drug: Trinase |
| Placebo group | Placebo comparator | Patients received one identical-appearing placebo tablet orally 30 minutes before single-visit root canal treatment (RCT). RCT was performed using the same anesthesia, instrumentation, irrigation, and obturation protocol as the Trinase group. Postoperative pain was assessed using the Visual Analogue Scale (VAS) at 6, 12, 24, and 48 hours. Ibuprofen 400 mg was allowed as rescue analgesia if needed, and consumption was recorded. Receives: Drug: placebo capsule |
What is being measured
The primary outcome is the main question the study is designed to answer.
Post-operative pain intensity assessed by Visual Analogue Scale (VAS)
Pain intensity was recorded by patients on a 10-cm Visual Analogue Scale (VAS), where 0 = no pain and 100 = pain as bad as it could be. Scores were categorized as no pain (0-4 mm), mild (5-44 mm), moderate (45-74 mm), severe (75-100 mm). Pain intensity was measured at baseline and at 6, 12, 24, and 48 hours after root canal treatment.
Measured: Baseline, 6, 12, 24, and 48 hours after root canal treatment
Secondary outcomes (1)
Number of analgesic tablets consumed within 48 hours post-treatment
Total number of rescue analgesic tablets (ibuprofen 400 mg) taken by patients within 48 hours after root canal treatment, as recorded or provided in patient charts during follow-up.
Measured: Within 48 hours post-treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Nov 2025
- Study start1 Aug 2025
- Primary completion5 Jan 2026
- Study completion5 Jan 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Symptomatic Irreversible Pulpitis (SIP)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants are randomized into two parallel groups: Trinase vs. placebo.
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 400 participants (actual)
Sponsor and investigators
- Lead sponsor
- Fayoum University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Sara Elmallah, Fayoum University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07239505
- Sponsor's protocol ID
- 102517
- Status last verified
- Sep 2026
- First submitted
- 16 Nov 2025
- Last updated
- 30 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: De-identified individual participant data (IPD) including demographics, baseline VAS, postoperative VAS scores (6, 12, 24, 48h), and analgesic consumption will be shared. Data will be anonymized (no names, IDs, or dates) and provided in CSV/SPSS format. IPD will be available 6 months after publication of primary results and for 5 years thereafter. Access requires a signed data use agreement specifying research purpose and ethics approval. Contact: Dr. Sara Samir Elmallah (sara.elmallah@fayoum.edu.eg).
Study at a glance
From the registry record, last updated by the sponsor on 30 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Role Of Trinase In Reducing Post-Operative Pain For Patients With Symptomatic Irreversible Pulpitis: A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07239505
- Acronym / sponsor ID
- 102517
- Conditions
- Symptomatic Irreversible Pulpitis (SIP), Postoperative Pain After Endodontic Treatment, Endodontic Disease, Dental Pain
- Keywords
- Visual Analogue Scale (VAS), Randomized Controlled Trial, Trinase, Postoperative Pain
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 400 participants (actual)
- Lead sponsor
- Fayoum UniversityUniversity, hospital or other
- Study start
- 1 Aug 2025 (actual)
- Primary completion
- 5 Jan 2026 (actual)
- Study completion
- 5 Jan 2026 (actual)
- First posted
- 20 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to determine whether Trinase, an enzyme-based anti-inflammatory medication, can reduce pain after root canal treatment in patients with symptomatic irreversible pulpitis. A total of 400 male patients aged 18 to 50 years who present with moderate to severe tooth pain were randomly assigned to receive either a Trinase tablet or a placebo 30 minutes before treatment. All root canal procedures were performed in a single visit using standard endodontic techniques.
Pain levels were measured on a Visual Analogue Scale (VAS) before treatment and at 6, 12, 24, and 48 hours after treatment. Patients recorded the number of pain-relief tablets they take during the first 48 hours. The goal of the study is to see whether Trinase can lower post-operative pain and reduce the need for analgesic medication compared with placebo. This information may help improve pain management for patients undergoing root canal therapy.
Detailed description
Symptomatic irreversible pulpitis is a common endodontic condition characterized by severe inflammatory dental pain. Although root canal treatment (RCT) is effective in removing the inflamed pulp tissue, many patients continue to experience pain during the first 24-48 hours after treatment. Post-operative endodontic pain affects patient comfort, satisfaction, and clinical workflow, making pain control an essential component of evidence-based endodontic care.
Traditional pharmacological methods for managing post-operative dental pain include nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. While these medications are effective, they are also associated with potential gastrointestinal and systemic adverse effects, especially when used repeatedly. As a result, there is growing interest in alternatives that can reduce inflammation and discomfort while minimizing systemic risks. Enzyme-based anti-inflammatory therapies, including combinations of trypsin, bromelain, and rutin, have been shown in medical and dental literature to provide meaningful reductions in pain, edema, and inflammation following surgical procedures. These proteolytic enzymes act by breaking down inflammatory mediators, reducing tissue permeability, and modulating cytokine responses. Trinase, a formulation containing trypsin, bromelain, and rutin, is widely used in postoperative care in other medical fields, yet its role in managing pain following endodontic procedures has not been adequately studied.
This randomized, double-blind, placebo-controlled clinical trial is designed to evaluate whether administering Trinase before root canal treatment can reduce the intensity of post-operative pain in patients diagnosed with symptomatic irreversible pulpitis. A total of 400 systemically healthy male patients, aged 18 to 50 years, were recruited from the Endodontics Department at Fayoum University. The study population is limited to male participants to standardize biological pain variability and hormonal influences on pain perception. Eligible patients presented with restorable mandibular molar teeth and moderate to severe preoperative pain confirmed both clinically and radiographically.
Participants were randomly assigned to one of two equal study arms. The Trinase group received a single oral Trinase tablet 30 minutes before treatment. The placebo group received a visually identical tablet administered under the same conditions. An assistant not involved in treatment prepared and code all medication envelopes, ensuring allocation concealment. Both the operator and the participants were blinded to group assignment.
All treatments were performed in a single visit using standardized endodontic procedures. After local anesthesia, rubber-dam isolation, and access preparation, canal patency were confirmed using stainless steel hand files. Working length determined electronically and confirmed radiographically. Mechanical instrumentation were performed using Protaper Next rotary instruments according to manufacturer instructions. Irrigation will be performed using 2.5% sodium hypochlorite and EDTA gel lubricant. Upon completion of cleaning and shaping, canals will be dried, obturated using a modified single-cone technique with resin-based sealer, and restored temporarily with intermediate restorative material. All procedures are performed by a single experienced operator to eliminate inter-operator variability.
The primary outcome measure is postoperative pain intensity assessed using a 10-cm Visual Analogue Scale (VAS). Patients will record their pain levels at baseline and at 6, 12, 24, and 48 hours after treatment. Pain will be categorized using validated VAS cutoff values. The secondary outcome measure is the total number of analgesic tablets consumed within 48 hours following treatment. Participants will receive a standardized pain diary to document both pain levels and analgesic intake.
Statistical analysis will be conducted using non-parametric tests due to expected non-normal distribution of pain scores. Between-group differences will be analyzed using the Mann-Whitney test, and within-group comparisons across time points will be performed using the Friedman test followed by appropriate post-hoc analysis. The significance level will be set at p ≤ 0.05. Sample size was calculated using PS software to detect clinically relevant differences in postoperative pain with an anticipated dropout rate accounted for by enrolling 400 participants.
The study protocol has been reviewed and approved by the Fayoum University Supreme Committee for Scientific Research Ethics (FU-SCSRE). Written informed consent will be obtained from each participant. The study involves minimal risk, as Trinase is a commercially available medication with a well-established safety profile and the placebo carries no known risks. The duration of active participation for each subject is approximately 48 hours, corresponding to the postoperative observation period. No additional radiographs or invasive procedures beyond standard clinical care will be performed.
This study aims to determine whether Trinase can serve as a simple, safe, and effective adjunct to improve postoperative patient comfort following root canal therapy. The results may help clarify the role of enzyme-based anti-inflammatory medications in endodontic pain management and potentially reduce reliance on traditional analgesics with known adverse effects.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- Participants are randomized into two parallel groups: Trinase vs. placebo.
| Arm | Type | Receives |
|---|---|---|
| Trinase group | Experimental | Drug: TrinasePatients received one tablet of Trinase (trypsin, bromelain, and rutin) orally 30 minutes before single-visit root canal treatment (RCT). RCT was performed under local anesthesia (2% lidocaine with 1:80,000 epinephrine) using a rubber dam and standard endodontic techniques. Postoperative pain was assessed using the Visual Analogue Scale (VAS) at 6, 12, 24, and 48 hours. Ibuprofen 400 mg was allowed as rescue analgesia if needed, and consumption was recorded. |
| Placebo group | Placebo comparator | Drug: placebo capsulePatients received one identical-appearing placebo tablet orally 30 minutes before single-visit root canal treatment (RCT). RCT was performed using the same anesthesia, instrumentation, irrigation, and obturation protocol as the Trinase group. Postoperative pain was assessed using the Visual Analogue Scale (VAS) at 6, 12, 24, and 48 hours. Ibuprofen 400 mg was allowed as rescue analgesia if needed, and consumption was recorded. |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Systemically healthy male patients (ASA I or II)
- Aged 18 to 50 years
- Presenting with symptomatic irreversible pulpitis in a restorable mandibular molar
- Preoperative moderate to severe pain (VAS ≥45 mm)
- Normal periapical tissue (no radiolucency, pocket depth ≤5 mm, mobility ≤ Grade I)
Key exclusion criteria (8 listed)
- Medically compromised patients (ASA III or higher)
- History of allergy or intolerance to Trinase or any of its components (trypsin, bromelain, rutin)
- Vertical root fracture
- External or internal root resorption
- Periodontal pocket depth >5 mm
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TrinaseOne tablet of Trinase (proteolytic enzyme combination: trypsin, bromelain, and rutin) administered orally 30 minutes prior to root canal treatment. Used as premedication to reduce postoperative pain and inflammation. | Drug | Trinase group |
| placebo capsuleOne identical-appearing placebo tablet administered orally 30 minutes prior to root canal treatment. Used as control. | Drug | Placebo group |
Primary outcome
Post-operative pain intensity assessed by Visual Analogue Scale (VAS)
Time frame: Baseline, 6, 12, 24, and 48 hours after root canal treatment
Pain intensity was recorded by patients on a 10-cm Visual Analogue Scale (VAS), where 0 = no pain and 100 = pain as bad as it could be. Scores were categorized as no pain (0-4 mm), mild (5-44 mm), moderate (45-74 mm), severe (75-100 mm). Pain intensity was measured at baseline and at 6, 12, 24, and 48 hours after root canal treatment.
1 secondary outcome
Number of analgesic tablets consumed within 48 hours post-treatment
Time frame: Within 48 hours post-treatment
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Sep 2026.
- Description: Official ClinicalTrials.gov record for this study (NCT number assigned upon submission)Link provided by the sponsor.
- Individual participant dataSharing planned: Yes. De-identified individual participant data (IPD) including demographics, baseline VAS, postoperative VAS scores (6, 12, 24, 48h), and analgesic consumption will be shared. Data will be anonymized (no names, IDs, or dates) and provided in CSV/SPSS format. IPD will be available 6 months after publication of primary results and for 5 years thereafter. Access requires a signed data use agreement specifying research purpose and ethics approval. Contact: Dr. Sara Samir Elmallah (sara.elmallah@fayoum.edu.eg).
Related trials for Symptomatic Irreversible Pulpitis (SIP)
Not yet recruiting
Comparison of Postoperative Pain After Root Canal Treatment Using Hand-Held vs Rotary ProTaper Files: A Randomized Controlled Trial
Symptomatic Irreversible Pulpitis (SIP), Symptomatic Apical Periodontitis
Recruiting
Short Term Comparative Assessment of MTA and Biodentine in Complete Pulpotomy for Symptomatic Irreversible Pulpitis
Symptomatic Irreversible Pulpitis (SIP)
Recruiting
Outcome of Partial Pulpotomy in Permanent Mandibular Molars With Symptomatic Irreversible Pulpitis After Wound Lavage With Calcium Hypochlorite or Sodium Hypochlorite
Symptomatic Irreversible Pulpitis (SIP), Extremely Deep Caries
RecruitingEarly Phase 1
Comparison Of Acetaminophen, NSAIDs, And Trypsin-Chymotrypsin Plus Acetaminophen For Post-Endodontic Pain After Single-Visit Root Canal Treatment
Symptomatic Irreversible Pulpitis (SIP)
Not yet recruiting
Effect of Preoperative Diclofenac Potassium Dose on Endodontic Pain
Symptomatic Irreversible Pulpitis (SIP)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Trinase in people with Symptomatic Irreversible Pulpitis (SIP) and Postoperative Pain After Endodontic Treatment, run by Fayoum University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Post-operative pain intensity assessed by Visual Analogue Scale (VAS) (time frame: Baseline, 6, 12, 24, and 48 hours after root canal treatment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Sep 2026.